Back to list
August 7, 2012
Category: Product News | Industrial & Customer Specialties | Corporate News

Clariant presents its new promise to pharma industry at CPhI 2012

Muttenz, August 7, 2012 – Clariant’s promise to create added value by appreciating the needs of its pharmaceutical sector customers will take center stage at the CPhI 2012, Booth #5H23.

Presented for the first time under the company’s new branding, the specialty chemicals expert’s trusted high purity, high quality tailored processing solutions can help meet the efficiency and performance requirements of specific pharmaceutical formulations.Clariant is a firm believer in working closely with customers in order to maximize the benefits of its extensive portfolio of building blocks, enhancers, and ingredients for the processing of sensitive applications.

A highlight for CPhI 2012 visitors will be Clariant’s broad portfolio of Pharmaceutical PEGs/ Macrogols, a leading product range under the trade name Polyglykol, used as API in laxatives and as excipients for tablets, suppository masses, organ preservation, protein purification and drug delivery systems. Clariant offers a complete range of different molecular weight, high purity PEGs supported by CEP certification and DMF.

“Appreciation is the key to delivering the innovative and competitive processing solutions required by the pharmaceutical sector. This philosophy of listening to our customers is at the heart of Clariant and we are excited to have the opportunity to present this to the pharmaceutical community within the fresh look and feel of our new company branding at the forthcoming CPhI,” comments Boris Segalowitch, Business Line Head Personal Care EMEA, Clariant.

Visit Clariant at Booth #5H23 CPhI 2012 October 9 – 11, 2012, Madrid, Spain.

print article
Clariant Media Contact
Global Media Office
Tel: +41 61 469 6363
Image Gallery
Find management and site pictures as well as Clariant logo in our media gallery Media Gallery
News Subscription
Newsletter
Loading...Loading...
Your Name:
Your Email:
Disclaimer